## Qiang Shen

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3109540/publications.pdf

Version: 2024-02-01

87888 106344 4,490 104 38 65 citations g-index h-index papers 105 105 105 7390 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Cancer drug delivery in the nano era: An overview and perspectives. Oncology Reports, 2017, 38, 611-624.	2.6	310
2	The role of STAT3 in leading the crosstalk between human cancers and the immune system. Cancer Letters, 2018, 415, 117-128.	7.2	237
3	Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention. Cancers, 2014, 6, 926-957.	3.7	234
4	Small Molecule Inhibitors Targeting Activator Protein 1 (AP-1). Journal of Medicinal Chemistry, 2014, 57, 6930-6948.	6.4	195
5	Gemcitabine treatment promotes pancreatic cancer stemness through the Nox/ROS/NF-κB/STAT3 signaling cascade. Cancer Letters, 2016, 382, 53-63.	7.2	134
6	Discovery and development of natural product oridonin-inspired anticancer agents. European Journal of Medicinal Chemistry, 2016, 122, 102-117.	5 <b>.</b> 5	132
7	TRPM7 mediates breast cancer cell migration and invasion through the MAPK pathway. Cancer Letters, 2013, 333, 96-102.	7.2	130
8	Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide. Oncogene, 2018, 37, 5292-5304.	5.9	122
9	Effect of cadmium on oxidative stress and immune function of common carp (Cyprinus carpio L.) by transcriptome analysis. Aquatic Toxicology, 2017, 192, 171-177.	4.0	121
10	Upâ€regulation of glycolysis promotes the stemness and <scp>EMT</scp> phenotypes in gemcitabineâ€resistant pancreatic cancer cells. Journal of Cellular and Molecular Medicine, 2017, 21, 2055-2067.	3.6	119
11	The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors. Oncogene, 2008, 27, 366-377.	5.9	113
12	Discovery of <i>O</i> -Alkylamino-Tethered Niclosamide Derivatives as Potent and Orally Bioavailable Anticancer Agents. ACS Medicinal Chemistry Letters, 2013, 4, 180-185.	2.8	108
13	Novel Nitrogen-Enriched Oridonin Analogues with Thiazole-Fused A-Ring: Protecting Group-Free Synthesis, Enhanced Anticancer Profile, and Improved Aqueous Solubility. Journal of Medicinal Chemistry, 2013, 56, 5048-5058.	6.4	97
14	Downregulation of ACE2/Ang-(1–7)/Mas axis promotes breast cancer metastasis by enhancing store-operated calcium entry. Cancer Letters, 2016, 376, 268-277.	7.2	92
15	Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy. European Journal of Medicinal Chemistry, 2013, 62, 498-507.	5 <b>.</b> 5	91
16	Mitochondrial Ca2+ uniporter is critical for store-operated Ca2+ entry-dependent breast cancer cell migration. Biochemical and Biophysical Research Communications, 2015, 458, 186-193.	2.1	90
17	Effect of Epidermal Growth Factor Receptor Inhibitor on Development of Estrogen Receptor-Negative Mammary Tumors. Journal of the National Cancer Institute, 2003, 95, 1825-1833.	6.3	89
18	Therapeutic Potential of Oridonin and Its Analogs: From Anticancer and Antiinflammation to Neuroprotection. Molecules, 2018, 23, 474.	3.8	85

#	Article	IF	CITATIONS
19	Humanized NOD-SCID IL2rg $\hat{a} \in \hat{a} \in \hat{a}$ mice as a preclinical model for cancer research and its potential use for individualized cancer therapies. Cancer Letters, 2014, 344, 13-19.	7.2	80
20	Knockdown of IncRNA H19 restores chemo-sensitivity in paclitaxel-resistant triple-negative breast cancer through triggering apoptosis and regulating Akt signaling pathway. Toxicology and Applied Pharmacology, 2018, 359, 55-61.	2.8	80
21	Chlorpyrifos exposure in common carp (Cyprinus carpio L.) leads to oxidative stress and immune responses. Fish and Shellfish Immunology, 2017, 67, 604-611.	3.6	78
22	Novel roles of reactive oxygen species in the pathogenesis of acute myeloid leukemia. Journal of Leukocyte Biology, 2013, 94, 423-429.	3.3	77
23	The microRNAs miR-200b-3p and miR-429-5p target the LIMK1/CFL1 pathway to inhibit growth and motility of breast cancer cells. Oncotarget, 2017, 8, 85276-85289.	1.8	70
24	cFos is critical for MCF-7 breast cancer cell growth. Oncogene, 2005, 24, 6516-6524.	5.9	64
25	Oridonin Ring A-Based Diverse Constructions of Enone Functionality: Identification of Novel Dienone Analogues Effective for Highly Aggressive Breast Cancer by Inducing Apoptosis. Journal of Medicinal Chemistry, 2013, 56, 8814-8825.	6.4	64
26	AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity. Oncogene, 2004, 23, 8238-8246.	5.9	63
27	Targeting STAT3/miR-21 axis inhibits epithelial-mesenchymal transition via regulating CDK5 in head and neck squamous cell carcinoma. Molecular Cancer, 2015, 14, 213.	19.2	63
28	Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways. Journal of Mammary Gland Biology and Neoplasia, 2003, 8, 45-73.	2.7	62
29	Overcoming Synthetic Challenges of Oridonin A-Ring Structural Diversification: Regio- and Stereoselective Installation of Azides and 1,2,3-Triazoles at the C-1, C-2, or C-3 Position. Organic Letters, 2013, 15, 3718-3721.	4.6	55
30	Mitochondrial calcium uniporter as a target of microRNA-340 and promoter of metastasis via enhancing the Warburg effect. Oncotarget, 2017, 8, 83831-83844.	1.8	55
31	Molecular cloning of a cDNA encoding the neuropeptides APGWamide and cerebral peptide 1: Localization of APGWamide-like immunoreactivity in the central nervous system and male reproductive organs of Aplysia., 1997, 387, 53-62.		54
32	Oridonin and its derivatives for cancer treatment and overcoming therapeutic resistance. Genes and Diseases, 2021, 8, 448-462.	3.4	54
33	Discovery of potent anticancer agent HJC0416, an orally bioavailable small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3). European Journal of Medicinal Chemistry, 2014, 82, 195-203.	5.5	52
34	Oxidative Stress Upregulates PDCD4 Expression in Patients with Gastric Cancer via miR-21. Current Pharmaceutical Design, 2014, 20, 1917-1923.	1.9	52
35	The Rexinoid LG100268 Prevents the Development of Preinvasive and Invasive Estrogen Receptor–Negative Tumors in MMTV-erbB2 Mice. Clinical Cancer Research, 2007, 13, 6224-6231.	7.0	46
36	Effect of Lapatinib on the Development of Estrogen Receptor–Negative Mammary Tumors in Mice. Journal of the National Cancer Institute, 2009, 101, 107-113.	6.3	46

#	Article	IF	CITATIONS
37	Suppression of the Growth and Invasion of Human Head and Neck Squamous Cell Carcinomas via Regulating STAT3 Signaling and the miR- $21\hat{l}^2$ -catenin Axis with HJC0152. Molecular Cancer Therapeutics, 2017, 16, 578-590.	4.1	45
38	Traditional Chinese medicine targeting apoptotic mechanisms for esophageal cancer therapy. Acta Pharmacologica Sinica, 2016, 37, 295-302.	6.1	43
39	Peiminine inhibits colorectal cancer cell proliferation by inducing apoptosis and autophagy and modulating key metabolic pathways. Oncotarget, 2017, 8, 47619-47631.	1.8	43
40	ent-Kaurane-based regio- and stereoselective inverse electron demand hetero-Diels–Alder reactions: synthesis of dihydropyran-fused diterpenoids. Organic and Biomolecular Chemistry, 2014, 12, 8442-8452.	2.8	41
41	ROS/KRAS/AMPK Signaling Contributes to Gemcitabine-Induced Stem-like Cell Properties in Pancreatic Cancer. Molecular Therapy - Oncolytics, 2019, 14, 299-312.	4.4	40
42	Multiple myeloma cell-derived IL- $32\hat{l}^3$ increases the immunosuppressive function of macrophages by promoting indoleamine 2,3-dioxygenase (IDO) expression. Cancer Letters, 2019, 446, 38-48.	7.2	39
43	Value of folate receptor-positive circulating tumour cells in the clinical management of indeterminate lung nodules: A non-invasive biomarker for predicting malignancy and tumour invasiveness. EBioMedicine, 2019, 41, 236-243.	6.1	38
44	MiR-519d-3p suppresses breast cancer cell growth and motility via targeting LIM domain kinase 1. Molecular and Cellular Biochemistry, 2018, 444, 169-178.	3.1	36
45	The AP-1 transcription factor regulates postnatal mammary gland development. Developmental Biology, 2006, 295, 589-603.	2.0	35
46	The rexinoid bexarotene represses cyclin D1 transcription by inducing the DEC2 transcriptional repressor. Breast Cancer Research and Treatment, 2011, 128, 667-677.	2.5	34
47	High glucose promotes pancreatic cancer cells to escape from immune surveillance via AMPK-Bmi1-GATA2-MICA/B pathway. Journal of Experimental and Clinical Cancer Research, 2019, 38, 192.	8.6	33
48	The microRNA miR-181c enhances chemosensitivity and reduces chemoresistance in breast cancer cells via down-regulating osteopontin. International Journal of Biological Macromolecules, 2019, 125, 544-556.	<b>7.</b> 5	33
49	Regio- and Stereospecific Synthesis of Oridonin D-Ring Aziridinated Analogues for the Treatment of Triple-Negative Breast Cancer via Mediated Irreversible Covalent Warheads. Journal of Medicinal Chemistry, 2018, 61, 2737-2752.	6.4	32
50	Dendritic Cells Loaded with Pancreatic Cancer Stem Cells (CSCs) Lysates Induce Antitumor Immune Killing Effect In Vitro. PLoS ONE, 2014, 9, e114581.	2.5	31
51	Polydatin down-regulates the phosphorylation level of Creb and induces apoptosis in human breast cancer cell. PLoS ONE, 2017, 12, e0176501.	2.5	31
52	Targeting the NRF-2/RHOA/ROCK signaling pathway with a novel aziridonin, YD0514, to suppress breast cancer progression and lung metastasis. Cancer Letters, 2018, 424, 97-108.	7.2	30
53	Rexinoid-induced Expression of IGFBP-6 Requires RARβ-dependent Permissive Cooperation of Retinoid Receptors and AP-1. Journal of Biological Chemistry, 2009, 284, 345-353.	3.4	26
54	Transgenic mouse models for the prevention of breast cancer. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005, 576, 93-110.	1.0	25

#	Article	IF	CITATIONS
55	HJC0152 suppresses human non–smallâ€cell lung cancer by inhibiting STAT3 and modulating metabolism. Cell Proliferation, 2020, 53, e12777.	5.3	24
56	Qigesan inhibits migration and invasion of esophageal cancer cells via inducing connexin expression and enhancing gap junction function. Cancer Letters, 2016, 380, 184-190.	7.2	21
57	GRB2 enforces homology-directed repair initiation by MRE11. Science Advances, 2021, 7, .	10.3	21
58	Targeting the Activator Protein 1 Transcription Factor for the Prevention of Estrogen Receptor–Negative Mammary Tumors. Cancer Prevention Research, 2008, 1, 45-55.	1.5	20
59	Calcium-sensing stromal interaction molecule 2 upregulates nuclear factor of activated T cells 1 and transforming growth factor- $\hat{l}^2$ signaling to promote breast cancer metastasis. Breast Cancer Research, 2019, 21, 99.	5.0	19
60	Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreatic cancer cells. Cell and Bioscience, 2019, 9, 50.	4.8	19
61	Bmi1 inhibition enhances the sensitivity of pancreatic cancer cells to gemcitabine. Oncotarget, 2016, 7, 37192-37204.	1.8	18
62	Hepatic Ischemic Preconditioning Alleviates Ischemia-Reperfusion Injury by Decreasing TIM4 Expression. International Journal of Biological Sciences, 2018, 14, 1186-1195.	6.4	15
63	Structure-activity relationship studies on Bax activator SMBA1 for the treatment of ER-positive and triple-negative breast cancer. European Journal of Medicinal Chemistry, 2019, 178, 589-605.	5.5	12
64	Identification of a novel SP3 binding site in the promoter of human IGFBP4 gene: role of SP3 and AP-1 in regulating promoter activity in CaCo2 cells. Oncogene, 2004, 23, 2454-2464.	5.9	8
65	Macranthoidin B Modulates Key Metabolic Pathways to Enhance ROS Generation and Induce Cytotoxicity and Apoptosis in Colorectal Cancer. Cellular Physiology and Biochemistry, 2018, 46, 1317-1330.	1.6	8
66	Pancreatic stromal Gremlin $1$ expression during pancreatic tumorigenesis. Genes and Diseases, 2022, 9, 108-115.	3.4	7
67	Further lead optimization on Bax activators: Design, synthesis and pharmacological evaluation of 2-fluoro-fluorene derivatives for the treatment of breast cancer. European Journal of Medicinal Chemistry, 2021, 219, 113427.	5.5	7
68	A novel STAT3 inhibitor, HJC0152, exerts potent antitumor activity in glioblastoma. American Journal of Cancer Research, 2019, 9, 699-713.	1.4	7
69	Efficacy and Safety of Nedaplatin in Advanced Breast Cancer Therapy. Cancer Investigation, 2016, 34, 167-172.	1.3	6
70	Characteristic pancreatic and splenic immune cell infiltration patterns in mouse acute pancreatitis. Cell and Bioscience, 2021, 11, 28.	4.8	6
71	Mechanistic Evaluation and Translational Signature of Gemcitabine-induced Chemoresistance by Quantitative Phosphoproteomics Analysis with iTRAQ Labeling Mass Spectrometry. Scientific Reports, 2017, 7, 12891.	3.3	5
72	Exploring cisplatin resistance in ovarian cancer through integrated bioinformatics approach and overcoming chemoresistance with sanguinarine. American Journal of Translational Research (discontinued), 2020, 12, 923-939.	0.0	5

#	Article	IF	CITATIONS
73	Expression of interleukin-32 in bone marrow of patients with myeloma and its prognostic significance. World Journal of Clinical Cases, 2019, 7, 4234-4244.	0.8	3
74	Abstract 3: Discovery and optimization of small molecule Bax activators for cancer therapy. , 2019, , .		2
75	Editorial: "Non-Coding RNAs in Head and Neck Squamous Cell Carcinoma― Frontiers in Oncology, 2021, 11, 785001.	2.8	2
76	Abstract P6-12-04: Targeting STAT3 with novel small molecule inhibitors to sensitize breast cancer cells to radiation therapy. , $2015,  ,  .$		1
77	Abstract P1-02-08: Reprogramming glucose metabolism and energy production in breast cancer cells. , 2018, , .		1
78	Abstract A95: KCNK5 regulates proliferation of ER-negative breast cancer cells. , 2010, , .		1
79	Abstract B85: Role of the TASK2 in regulating breast cancer cell proliferation. , 2011, , .		1
80	Abstract 5066: Chemoprevention of breast cancer by targeting glucose metabolism with HJC0152. , 2019, , .		1
81	Structure-activity relationship studies on O-alkylamino-tethered salicylamide derivatives with various amino acid linkers as potent anticancer agents. European Journal of Medicinal Chemistry, 2022, 234, 114229.	5 <b>.</b> 5	1
82	Cellular crosstalk mediating immune evasion in pancreatic cancer microenvironment. Annals of Pancreatic Cancer, $0, 2, 13-13$ .	1.2	0
83	Distinct Murine Pancreatic Transcriptomic Signatures during Chronic Pancreatitis Recovery. Mediators of Inflammation, 2021, 2021, 1-13.	3.0	0
84	Abstract 1238: Treating estrogen receptor (ER)-negative and triple-negative breast cancer by targeting STAT3 signaling with putative STAT3 inhibitors. , $2021$ , , .		0
85	Abstract 1239: Putative Bax activators GL0385 and GL0388 for targeted breast cancer therapy., 2021,,.		0
86	Abstract B82: The TASK2 potassium ion channel is differentially expressed in ERâ€negative breast cancer. , 2010, , .		0
87	Abstract B63: Developing Novel STAT3 Inhibitors for the Treatment and Prevention of Cancer. Cancer Prevention Research, 2012, 5, B63-B63.	1.5	0
88	Abstract 5573: Discovery of potent oridonin derivatives for the treatment of breast cancer, 2013, , .		0
89	Abstract 872: Novel potent and orally active STAT3 inhibitors for cancer therapies, 2013, , .		0
90	Abstract 2267: Natural product-inspired drug discovery: Chemistry and biology of oridonin analogs with unique scaffolds and enhanced anticancer profiles, 2013, , .		0

#	Article	IF	CITATIONS
91	Abstract B33: Target STAT3 signaling for the prevention of ER-negative breast cancer., 2013,,.		0
92	Abstract 5317: Photonic crystal microarray sensing of breast cancer cell line lysates. , 2014, , .		0
93	Abstract 3805: Anticancer agent HJC0416 inhibits the growth of breast cancer xenografts via downregulating STAT3 signaling. , $2014$ , , .		0
94	Abstract 329: Reprogramming glucose metabolism and energy production with a small molecule HJC0152 suppresses breast cancer development and progression to metastasis. , 2016, , .		0
95	Abstract 9: Suppression of the invasion and growth of human head and neck squamous cell carcinomas via regulating STAT3 signaling and miR-21 $\hat{l}^2$ -catenin axis with HJC0152., 2017,,.		0
96	Abstract LB-299: Glucose metabolism modulator HJC0152 differentially regulates glycolytic enzymes to suppress breast carcinogenesis., 2017,,.		0
97	Abstract P5-21-19: Suppression of breast carcinogenesis and metastasis by targeting glucose metabolism with HJC0152. , 2018, , .		0
98	Abstract P3-06-09: Discovery of novel oridonin-derivatives for the treatment of metastatic breast cancer., 2018,,.		0
99	Abstract 4883: Suppression of breast cancer by reprogramming glucose metabolism and energy production with HJC0152. , 2018, , .		0
100	Abstract 2668: Regio- and stereospecific synthesis of oridonin D-ring aziridinated analogues for the treatment of triple-negative breast cancer via mediated irreversible covalent warheads. , 2018, , .		0
101	Abstract P2-06-13: A novel small molecule JMX0293 inhibits the growth of triple-negative breast cancer via suppressing STAT3 and inducing apoptosis. , 2019, , .		0
102	Abstract P6-03-19: Oridonalogs reverse chemoresistance in breast cancer cells by targeting STAT3. , 2020, , .		0
103	Abstract 19: Examination of HJC0152, a putative modulator of glucose and energy metabolism, for mammary cancer prevention. , 2020, , .		0
104	Abstract 3: Discovery and optimization of small molecule Bax activators for cancer therapy., 2019,,.		O